Live Breaking News & Updates on Ncology Center Of Excellence

FDA OKs 1st targeted drug for common lung cancer mutation
LINDA A. JOHNSON, AP Medical Writer
May 28, 2021
FacebookTwitterEmail
This image provided by Amgen in May 2021 shows packaging for their medication Lumakras. On Friday, May 28, 2021, the U.S. Food and Drug Administration approved Lumakras, the first medicine for adults with advanced non-small cell lung cancer whose tumors have a common genetic mutation long considered untreatable with drugs. Each year, about 13,000 U.S. patients are diagnosed with this cancer and mutation. (Amgen via AP)AP
FAIRLESS HILLS, PA. (AP) U.S. regulators have approved the first medicine for patients with the most common type of lung cancer whose tumors have a genetic mutation long considered untreatable with drugs. ....

Lindaa Johnson , Richard Pazdur , Davidm Reese , Oncology Center , Science Department , Associated Press Health , Howard Hughes Medical Institute , Richard Pazdur , Lindaa Johnson , United States , North America , Fairless Hills , C Complete State National , Ncology Center Of Excellence , Epartment Of Science Education , He Associated Press Health And Science Department , Howard Hughes Medical Institute , A Wire , Usiness Stories , Ews Health Stories , Op News , Usiness News , F Wire , Hoice Plus , Lung Cancer Drug , Ttps Twitter Com Lindaj Onpharma ,